ProQR Therapeutics N.V. - Ordinary Shares (PRQR): Price and Financial Metrics
GET POWR RATINGS... FREE!
PRQR POWR Grades
- PRQR scores best on the Growth dimension, with a Growth rank ahead of 55.25% of US stocks.
- PRQR's strongest trending metric is Stability; it's been moving down over the last 177 days.
- PRQR ranks lowest in Stability; there it ranks in the 3rd percentile.
PRQR Stock Summary
- With a price/sales ratio of 64.45, PROQR THERAPEUTICS NV has a higher such ratio than 96.98% of stocks in our set.
- With a year-over-year growth in debt of -45.79%, PROQR THERAPEUTICS NV's debt growth rate surpasses merely 5.98% of about US stocks.
- The volatility of PROQR THERAPEUTICS NV's share price is greater than that of 96.01% US stocks with at least 200 days of trading history.
- If you're looking for stocks that are quantitatively similar to PROQR THERAPEUTICS NV, a group of peers worth examining would be OGEN, GSIT, EIGR, MEIP, and PULM.
- PRQR's SEC filings can be seen here. And to visit PROQR THERAPEUTICS NV's official web site, go to www.proqr.com.
PRQR Price Target
For more insight on analysts targets of PRQR, see our PRQR price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
|Average Price Target||$25.19||Average Broker Recommendation||1.31 (Strong Buy)|
PRQR Stock Price Chart Interactive Chart >
PRQR Price/Volume Stats
|Current price||$1.99||52-week high||$3.85|
|Prev. close||$2.52||52-week low||$0.53|
|Day high||$2.79||Avg. volume||1,266,682|
|50-day MA||$2.99||Dividend yield||N/A|
|200-day MA||$1.65||Market Cap||141.87M|
ProQR Therapeutics N.V. - Ordinary Shares (PRQR) Company Bio
ProQR Therapeutics is a biopharmaceutical company, focused on RNA medicines for the treatment of severe diseases such as cystic fibrosis and Leber's congenital amaurosis. The company was founded in 2012 and is based in Leiden, the Netherlands.
Most Popular Stories View All
PRQR Latest News Stream
|Loading, please wait...|
PRQR Latest Social Stream
View Full PRQR Social Stream
Latest PRQR News From Around the Web
Below are the latest news stories about PROQR THERAPEUTICS NV that investors may wish to consider to help them evaluate PRQR as an investment opportunity.
Why Shares of ProQR Therapeutics Dropped on Wednesday
Shares of ProQR Therapeutics (NASDAQ: PRQR) were down 31% Wednesday morning after the company reported 2022 full-year earnings and updated the status of its pipeline. ProQR is a clinical-stage biopharmaceutical company that focuses on RNA-based therapies to treat rare genetic diseases, especially inherited eye diseases. ProQR released its fourth-quarter and full-year earnings before the market opened on Wednesday, along with an update regarding its pipeline.
ProQR Announces Initial Pipeline Targets and Highlights Axiomer® RNA Editing Platform Technology at R&D Event
Initial pipeline programs with liver delivery to address Cholestatic Diseases targeting NTCP and Cardiovascular Disease targeting B4GALT1; initiation of clinical trials anticipated in late 2024/early 2025Axiomer activity demonstrated across multiple preclinical in vitro, organoid, and in vivo models; up to 50% editing observed in rodent and non-human primatesBeyond correction, broad applicability of Axiomer demonstrated in preclinical models with ability to modulate proteins by altering function
ProQR Announces Successful Defense of a Key Axiomer® Patent Protecting ADAR-mediated RNA Editing
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 14, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against two oppositions that were filed against a key patent for its ADAR-mediated RNA editing platform Axiomer®. The oppositions were filed in February 2021 with the European Patent Office (EPO) by two separate strawmen against ProQR’s granted patent EP 3
ProQR to Present at Upcoming Scientific and Industry Conferences
LEIDEN, Netherlands & CAMBRIDGE, Mass., March 07, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced several presentations highlighting the Company’s proprietary Axiomer® RNA editing technology platform at upcoming scientific and industry conferences, including the 8th annual Oligonucleotide and Precision Therapeutics (OPT) Congress, March 13-14, 2023 in Boston, MA, U.S.; RNA Leaders
ProQR Therapeutics to Host Virtual R&D Event on March 29, 2023
LEIDEN, Netherlands & CAMBRIDGE, Mass., Feb. 28, 2023 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced that the Company will host a virtual R&D event on Wednesday, March 29, 2023 from 10:00 am until 12:30 pm EDT, including an Analyst Q&A session with members of the ProQR Management Team. During the event, the Company will showcase its proprietary Axiomer® RNA-editing technology platform
PRQR Price Returns
Continue Researching PRQRHere are a few links from around the web to help you further your research on ProQR Therapeutics NV's stock as an investment opportunity:
ProQR Therapeutics NV (PRQR) Stock Price | Nasdaq
ProQR Therapeutics NV (PRQR) Stock Quote, History and News - Yahoo Finance
ProQR Therapeutics NV (PRQR) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...